首页> 外文期刊>The Journal of toxicological sciences >Suppressive effect of liver tumor-promoting activities in rats subjected to combined administration of phenobarbital and piperonyl butoxide
【24h】

Suppressive effect of liver tumor-promoting activities in rats subjected to combined administration of phenobarbital and piperonyl butoxide

机译:苯巴比妥和胡椒基丁醚联合给药对大鼠肝肿瘤促进活性的抑制作用

获取原文
获取原文并翻译 | 示例
           

摘要

Phenobarbital (PB) is a cytochrome P450 (CYP) 2B inducer, and piperonyl butoxide (PBO) is a CYP1A/2B inducer. These inducers have liver tumor-promoting effects in rats. In this study, we performed a rat two-stage liver carcinogenesis bioassay to examine the tumor-promoting effect of PB and PBO co-administration. Male rats received an intraperitoneal injection of N-diethylnitrosamine (DEN) for initiation. Two weeks after DEN administration, rats were given PB (60 or 120 ppm in drinking water), PBO (1,250 or 2,500 ppm in diet) or 60 ppm PB+1,250 ppm PBO for 6 weeks. One week after the PB/PBO treatment, all rats were subjected to a two-thirds partial hepatectomy. To evaluate the effect of the combined administration, we used two statistical additive models. In the isoadditive model, the average values of the area of GST-P positive foci in the PB+PBO group were significantly lower than those in the High PB or High PBO groups. In the heteroadditive model, the net values of Cyp1a1 mRNA level and microsomal reactive oxygen species (ROS) production in the PB+PBO group were significantly lower than the sum of those in the Low PB or Low PBO groups. On the contrary, there was no interactive effect in the PCNA-positive hepatocyte ratio, mRNA levels of Cyp2b1/2, Gstm3, Gpx2 and Nqo1, and the level of thiobarbituric acid-reactive substances in the PB+PBO group. These results suggest that PB and PBO co-administration causes suppressive effects in liver tumor-promoting activity in rats resulting from inhibited microsomal ROS production because of suppression of CYP1A induction.
机译:苯巴比妥(PB)是细胞色素P450(CYP)2B诱导剂,而胡椒基丁醚(PBO)是CYP1A / 2B诱导剂。这些诱导剂在大鼠中具有促进肝肿瘤的作用。在这项研究中,我们进行了大鼠两阶段肝癌变生物测定,以研究PB和PBO共同给药对肿瘤的促进作用。雄性大鼠腹膜内注射N-二乙基亚硝胺(DEN)引发。 DEN给药后两周,给大鼠PB(饮用水中60或120 ppm),PBO(饮食中1,250或2,500 ppm)或60 ppm PB + 1,250 ppm PBO,持续6周。 PB / PBO治疗后一周,所有大鼠均接受了三分之二的肝部分切除术。为了评估联合给药的效果,我们使用了两个统计加性模型。在等加模型中,PB + PBO组中GST-P阳性灶面积的平均值显着低于High PB或High PBO组。在异加模型中,PB + PBO组的Cyp1a1 mRNA水平和微粒体活性氧(ROS)产生的净值显着低于Low PB或Low PBO组的总和。相反,PB + PBO组的PCNA阳性肝细胞比例,Cyp2b1 / 2,Gstm3,Gpx2和Nqo1的mRNA水平以及对硫代巴比妥酸反应性物质的水平没有交互作用。这些结果表明PB和PBO的共同给药对大鼠肝脏肿瘤促进活性产生抑制作用,这是由于抑制了CYP1A的诱导而抑制了微粒体ROS的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号